• Navidea Biopharmaceuticals Inc., of Dublin, Ohio, said it reached agreement with the FDA for two special protocol assessments for the company's pivotal Phase III program testing NAV5001 as an aid in the differential diagnosis of Parkinsonian syndromes from non-Parkinsonian tremor.